Arthneeti
All Q4 FY26 results →
C

Cipla Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Cipla Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,432
Market cap₹1.2L Cr
P/E32.7
Updated23 Aug 2026
Read4 min read

The short version

Cipla aims to achieve a $1 billion run rate in its U.S. Cipla expects robust growth with a $1 billion+ run rate in the U.S.

From Cipla Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Cipla aims to achieve a $1 billion run rate in its U.S. business by the end of FY '27, with significant growth expected from new product launches in respiratory, peptide, and other complex segments.
  • The India business is expected to grow at a double-digit rate in FY '27, driven by improved seasonality and robust performance across branded generics, trade generics, and consumer health care.
  • Growth in chronic therapies such as diabetes, cardiology, urology, and dermatology is a key focus area.
  • Cipla plans to accelerate R&D pipeline, especially in respiratory and biosimilars, aiming for 6 to 8 biosimilar assets over 5-8 years.
  • Expansion through selective inorganic opportunities, particularly in differentiated specialty products for developed markets like the U.S. and Europe.

2 more points from Cipla Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Cipla Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Cipla is preparing for solid growth over the next 5 years and beyond, focusing capital deployment primarily on R&D to accelerate its pipeline, especially in Respiratory, Complex products (peptides, differentiated products), and biosimilars (targeting 6 to 8 in-house assets).
  • Capital expenditure (capex) has increased steadily over the last 3 years, but the cycle will probably reduce after another year as enough manufacturing capacity has been built.
  • Future investments will be more focused on productivity initiatives rather than capacity expansion.
  • In terms of inorganic investments, Cipla is interested in acquiring differentiated specialty products and capabilities in developed markets (U.S. and Europe) to sustain long-term growth.

2 more points from Cipla Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript and document do not provide specific details on Cipla Limited's current or expected order book or pending orders. However, key relevant insights related to Cipla's business outlook include: - Cipla is targeting a $1 billion plus run rate in their U.S. business in FY '27. - Significant new product launches, especially in respiratory and peptides, are expected to drive growth. - Order fulfillment and supply capacity appear robust, with no major constraints noted for products like Ventolin. - Firm confidence in double-digit growth in the India market in FY '27, driven by branded generics, trade generics, and consumer healthcare.

2 more points from Cipla Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Cipla Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹6.5K Cr, net profit ₹543 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Cipla's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cipla Ltd Q4 FY26 results?

Cipla aims to achieve a $1 billion run rate in its U.S. Cipla expects robust growth with a $1 billion+ run rate in the U.S.

What is Cipla Ltd share price analysis?

Cipla Ltd currently shows a neutral. The stock trades at a P/E of 32.7 with a market cap of ₹117,139 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cipla Ltd planning capital expenditure?

Cipla is preparing for solid growth over the next 5 years and beyond, focusing capital deployment primarily on R&D to accelerate its pipeline, especially in Respiratory, Complex products (peptides, differentiated products), and biosimilars (targeting 6 to 8 in-house assets).

Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.